CA3012190A1 - Compounds and methods for treating inflammation - Google Patents
Compounds and methods for treating inflammation Download PDFInfo
- Publication number
- CA3012190A1 CA3012190A1 CA3012190A CA3012190A CA3012190A1 CA 3012190 A1 CA3012190 A1 CA 3012190A1 CA 3012190 A CA3012190 A CA 3012190A CA 3012190 A CA3012190 A CA 3012190A CA 3012190 A1 CA3012190 A1 CA 3012190A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- amino acids
- chemerin
- composition
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662286070P | 2016-01-22 | 2016-01-22 | |
| US62/286,070 | 2016-01-22 | ||
| PCT/US2017/014605 WO2017127827A1 (en) | 2016-01-22 | 2017-01-23 | Compounds and methods for treating inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3012190A1 true CA3012190A1 (en) | 2017-07-27 |
Family
ID=57963487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3012190A Pending CA3012190A1 (en) | 2016-01-22 | 2017-01-23 | Compounds and methods for treating inflammation |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11197906B2 (https=) |
| EP (1) | EP3405208B1 (https=) |
| JP (3) | JP6924211B2 (https=) |
| AU (1) | AU2017210118B2 (https=) |
| CA (1) | CA3012190A1 (https=) |
| ES (1) | ES2805037T3 (https=) |
| WO (1) | WO2017127827A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014168721A2 (en) | 2013-04-12 | 2014-10-16 | Tufts Medical Center | Methods and systems for designing and/or characterizing soluble lipidated ligand agents |
| EP3405208B1 (en) | 2016-01-22 | 2020-04-29 | Tufts Medical Center, Inc. | Compounds and methods for treating inflammation |
| JP7251036B2 (ja) * | 2018-06-28 | 2023-04-04 | ポーラ化成工業株式会社 | 皮膚老化改善剤のスクリーニング方法 |
| US12559523B2 (en) | 2019-08-01 | 2026-02-24 | Okyo Pharma Limited | Compositions comprising chemerin analogs and methods of use |
| EP4522118A2 (en) * | 2022-05-12 | 2025-03-19 | Okyo Pharma Limited | Chemerin-containing formulation for treating dry eye disease |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6416738B1 (en) | 1973-12-07 | 2002-07-09 | Neorx Corporation | Pretargeting methods and compounds |
| US5200473A (en) | 1988-03-25 | 1993-04-06 | Jeanneret Gris Gilbert | Chelating resins and method for their use in the extraction of metal ions |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| CN1355690A (zh) | 1999-04-16 | 2002-06-26 | 奥赛尔股份有限公司 | 一种延长可溶性病毒特异性配体在粘膜上半寿期的方法 |
| IL160142A0 (en) | 2001-08-17 | 2004-06-20 | Anosys Inc | Methods and compounds for the targeting of protein to exosomes |
| US7169892B2 (en) | 2003-01-10 | 2007-01-30 | Astellas Pharma Inc. | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
| WO2004084950A2 (en) | 2003-03-24 | 2004-10-07 | Case Western Reserve University | Cell targeting methods and compositions |
| WO2005121755A1 (en) | 2004-06-14 | 2005-12-22 | Commonwealth Scientific And Industrial Research Organisation | Cell free g-protein coupled receptor and ligand assay |
| MX2007004676A (es) | 2004-10-27 | 2007-11-14 | Univ Denver | Analogos de la hormona adrenocorticotropica y metodos relacionados. |
| PL1891446T3 (pl) | 2005-06-14 | 2013-08-30 | Cellzome Gmbh | Sposób identyfikacji nowych związków oddziałujących z enzymami |
| US8242058B2 (en) | 2006-07-21 | 2012-08-14 | Wisconsin Alumni Research Foundation | Reagents and methods for appending functional groups to proteins |
| JP2010229093A (ja) | 2009-03-27 | 2010-10-14 | Banyu Pharmaceut Co Ltd | 新規ＣｈｅｍｅｒｉｎＲアゴニスト |
| GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
| WO2011034887A2 (en) | 2009-09-15 | 2011-03-24 | The Brigham And Women's Hospital, Inc. | A method for treating neuropathic pain |
| AU2011213631B2 (en) | 2010-02-08 | 2015-05-14 | Board Of Regents Of The University Of Nebraska | Biomineral and metal binding liposomes, their synthesis, and methods of use thereof |
| US8883177B2 (en) | 2011-06-28 | 2014-11-11 | Nian Wu | Pharmaceutical compositions for parenteral administration |
| HK1202064A1 (en) * | 2011-10-13 | 2015-09-18 | 托马斯．盖德克 | Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions |
| WO2014168721A2 (en) | 2013-04-12 | 2014-10-16 | Tufts Medical Center | Methods and systems for designing and/or characterizing soluble lipidated ligand agents |
| EP3405208B1 (en) | 2016-01-22 | 2020-04-29 | Tufts Medical Center, Inc. | Compounds and methods for treating inflammation |
-
2017
- 2017-01-23 EP EP17703290.1A patent/EP3405208B1/en active Active
- 2017-01-23 ES ES17703290T patent/ES2805037T3/es active Active
- 2017-01-23 AU AU2017210118A patent/AU2017210118B2/en active Active
- 2017-01-23 JP JP2018557295A patent/JP6924211B2/ja active Active
- 2017-01-23 CA CA3012190A patent/CA3012190A1/en active Pending
- 2017-01-23 US US16/070,467 patent/US11197906B2/en active Active
- 2017-01-23 WO PCT/US2017/014605 patent/WO2017127827A1/en not_active Ceased
-
2021
- 2021-07-30 JP JP2021125537A patent/JP2021169531A/ja active Pending
- 2021-11-08 US US17/521,366 patent/US12053501B2/en active Active
-
2023
- 2023-02-28 JP JP2023029552A patent/JP7432028B2/ja active Active
-
2024
- 2024-06-20 US US18/749,154 patent/US20240325486A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017210118B2 (en) | 2023-05-04 |
| JP7432028B2 (ja) | 2024-02-15 |
| JP6924211B2 (ja) | 2021-08-25 |
| US20240325486A1 (en) | 2024-10-03 |
| US20190022168A1 (en) | 2019-01-24 |
| JP2021169531A (ja) | 2021-10-28 |
| JP2019507182A (ja) | 2019-03-14 |
| US11197906B2 (en) | 2021-12-14 |
| US12053501B2 (en) | 2024-08-06 |
| JP2023059999A (ja) | 2023-04-27 |
| US20220054581A1 (en) | 2022-02-24 |
| AU2017210118A1 (en) | 2018-08-09 |
| EP3405208B1 (en) | 2020-04-29 |
| EP3405208A1 (en) | 2018-11-28 |
| ES2805037T3 (es) | 2021-02-10 |
| WO2017127827A1 (en) | 2017-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240325486A1 (en) | Methods for treating symptoms of dry eye disease | |
| JP2018111702A (ja) | 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド | |
| ES2393462T3 (es) | Péptido útil para inhibir la actividad del receptor de prosta-glandina F2X | |
| WO2023220676A2 (en) | Formulation for treating dry eye disease | |
| EP4007636B1 (en) | Compositions comprising bovine adrenal medulla 8-22 (bam8-22) peptide analogs and methods of use | |
| AU2020321898B2 (en) | Compositions comprising chemerin analogs and methods of use | |
| HK40000831A (en) | Compounds and methods for treating inflammation | |
| HK40000831B (en) | Compounds and methods for treating inflammation | |
| JP2018509395A (ja) | 筋肉の疾患および障害を治療するための方法および組成物 | |
| HK40097419A (en) | Compositions comprising chemerin analogs and methods of use | |
| WO2025265134A1 (en) | Compounds and methods for treating neuropathic ocular pain | |
| HK40075089A (en) | Compositions comprising chemerin analogs and methods of use | |
| HK40075089B (en) | Compositions comprising chemerin analogs and methods of use | |
| BR112015020143B1 (pt) | Composição tópica farmacêutica no tratamento ocular tópico e/ou na prevenção de doenças neurodegenerativas da retina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220121 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241002 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241224 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241224 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250115 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250519 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250519 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260113 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260113 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260203 |